Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to tame severe gut disease

NCT ID NCT07650942

Not yet recruiting Disease control Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental tablet called Hemay005 in 360 Chinese adults with moderate to severe ulcerative colitis, a chronic gut condition. Participants will receive either the drug or a placebo to see if it can bring about remission and improve symptoms over 12 weeks, with a follow-up phase up to 40 weeks. The goal is to control the disease, not cure it, as ongoing management is typically needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital,Sun Yat-Sen University

    Guangzhou, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Sixth Affiliated Hospital,Sun Yat-Sen University

    Guangzhou, China

    Contact Phone: •••-•••-••••

    Contact